Bristol Myers Squibb
Biopharmaceutical company with Camzyos (mavacamten), a cardiac myosin inhibitor with an adult indication for obstructive hypertrophic cardiomyopathy, pursuing a September 30, 2026 PDUFA date for adolescent obstructive HCM.
Princeton, NJ
1887
34000+
NYSE: BMY
Commercial Insurance, Medicaid, Medicare
What They Do
Bristol Myers Squibb is a global biopharmaceutical company. In the pediatric health context, it is advancing Camzyos (mavacamten) toward an adolescent indication for obstructive hypertrophic cardiomyopathy, with a PDUFA date of September 30, 2026. Clearance would take the cardiac myosin inhibitor into the pediatric cardiology market.
Competitive Position
Camzyos is the first approved cardiac myosin inhibitor for obstructive HCM. An adolescent label would extend an adult blockbuster into a pediatric population with no existing first-in-class competition.
Funding Rounds
No funding rounds on record for this company.